Pola-BR Regimen

**Semantic type:** Therapeutic or Preventive Procedure

**Definition:** A regimen consisting of polatuzumab vedotin, bendamustine and rituximab that may be used in the treatment of diffuse large B-cell lymphoma (DLBCL).

**Synonyms:** - Bendamustine and Rituximab (BR) and Polatuzumab vedotin - Bendamustine and Rituximab-abbs (BR) and Polatuzumab vedotin - Bendamustine and Rituximab-arrx (BR) and Polatuzumab vedotin - Bendamustine and Rituximab-blit (BR) and Polatuzumab vedotin - Bendamustine and Rituximab-pvvr (BR) and Polatuzumab vedotin - Bendamustine and Rituximab-rite (BR) and Polatuzumab vedotin - Bendamustine and Rituximab-rixa (BR) and Polatuzumab vedotin - Bendamustine and Rituximab-rixi (BR) and Polatuzumab vedotin - Bendamustine-Polatuzumab Vedotin-Rituximab - Bendamustine-Polatuzumab Vedotin-Rituximab Regimen - Bendamustine/Polatuzumab Vedotin/Rituximab - Bendamustine/Polatuzumab Vedotin/Rituximab Regimen - Bendamustine/Polivy/Rituxan Regimen - Polatuzumab Vedotin Plus Bendamustine/Rituximab - Polatuzumab Vedotin-BR Regimen - Polatuzumab Vedotin-Bendamustine/Rituximab Regimen - Polatuzumab Vedotin-piiq Plus Bendamustine/Rituximab